XOMA Corporation (NASDAQ:XOMA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
A number of other brokerages also recently issued reports on XOMA. Wedbush upgraded XOMA Corporation from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $9.00 to $19.00 in a research report on Tuesday, September 5th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of XOMA Corporation in a research report on Thursday, August 10th. Finally, ValuEngine upgraded XOMA Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $14.00.
XOMA Corporation (NASDAQ:XOMA) opened at 19.05 on Wednesday. XOMA Corporation has a 12 month low of $3.96 and a 12 month high of $19.35. The stock’s market capitalization is $144.74 million. The firm’s 50-day moving average is $9.48 and its 200-day moving average is $7.24.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/09/13/xoma-corporation-xoma-lowered-to-sell-at-zacks-investment-research.html.
An institutional investor recently raised its position in XOMA Corporation stock. California Public Employees Retirement System lifted its holdings in shares of XOMA Corporation (NASDAQ:XOMA) by 95.5% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 21,780 shares of the biotechnology company’s stock after acquiring an additional 10,640 shares during the period. California Public Employees Retirement System owned approximately 0.29% of XOMA Corporation worth $123,000 at the end of the most recent quarter. 32.92% of the stock is owned by institutional investors.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.